Physician profile
Gabriel Kind
NPI 1831130673
$4,260.04
in general payments reported to CMS, 2019-2025
14 companies · $505 in 2025
The $505 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $196 · 2021: $640 · 2022: $1,372 · 2023: $611 · 2024: $360 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rti Surgical, INC | $1,332.66 | 2022-2025 | |
| Abbvie INC. | $1,044.94 | 2023-2025 | |
| Allergan, INC. | $557.11 | 2021-2022 | |
| Integra Lifesciences Corporation | $494.00 | 2020-2022 | |
| Apyx Medical Corporation | $284.44 | 2019 | |
| Derma Sciences, INC. | $164.77 | 2019 | |
| Endo Pharmaceuticals INC. | $110.46 | 2019-2020 | |
| Axogen | $73.12 | 2019-2021 | |
| Access Pro Medical, LLC | $45.11 | 2025 | Matriderm |
| Conmed Corporation | $42.96 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $40.09 | 2020 | |
| Motiva USA, LLC | $29.13 | 2024-2025 | |
| Musculoskeletal Transplant Foundation INC. | $23.86 | 2024-2025 | |
| Sientra, INC. | $17.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Kind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.